AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-140607701/par-pharmaceutical-receives-final.html" title="Facts and information about Par Pharmaceutical receives final approval to market Generic Cefzil for oral suspension.">Par Pharmaceutical receives final approval to market Generic Cefzil for oral suspension.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Par Pharmaceutical receives final approval to market Generic Cefzil for oral suspension.
(From Chemical Business NewsBase - Press Release)
Par Pharmaceutical Companies Inc has received final approval from the US Food and Drug Administration for its abbreviated New Drug Application for cefprozil for oral suspension. Cefprozil is the generic version of Bristol-Myers Squibb company's broad-spectrum …
Related articles from newspapers, magazines, journals, and more
-
- FDA approves Santarus' Rapinex (omeprazole) powder for oral suspension 20 mg.
-
News wire article from: Asia Africa Intelligence Wire
June 15, 2004
700+ words
-
- Par Pharmaceutical receives final approval to market generic Questran powder...
-
News wire article from: Asia Africa Intelligence Wire
August 29, 2005
700+ words
-
- FDA Accepts BANZEL (Rufinamide) Oral Suspension NDA for Review.
-
News wire article from: Chemical Business Newsbase
July 19, 2010
700+ words
-
- Par Pharmaceutical Companies reports 4Q and full-year results for 2010.
-
News wire article from: Chemical Business Newsbase
February 24, 2011
700+ words
-
- Event Brief of Q3 2007 Par Pharmaceutical Companies, Inc. Earnings Conference...
-
News wire article from: Fair Disclosure Wire
December 20, 2007
700+ words
